OncoSynergy
Stamford, US · 1 known investors
OncoSynergy develops monoclonal antibodies for immuno-oncology, including first-in-class pan-CD29 and best-in-class PD1-targeting candidates. The company is focused on cancer immunotherapy.
BiotechHealthtechMedical Devices
Investors · 1
In the news
- OncoSynergy - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- The Innovators: OncoSynergy - CANCER FUNDcancerfund.com · 2021
- OncoSynergy makes series A headway -globalventuring.com · 2018
- OncoSynergy Raises Series A Funding Round - FinSMEsfinsmes.com · 2018
- DanDrit Biotech USA Inc. Announces The Purchase Of OncoSynergy, Inc.prnewswire.com · 2016
- OncoSynergy raises Series A Round to Accelerate Clinical Development of its Glioblastoma Program | UCSF Helen Diller Family Comprehensive Cancer Centercancer.ucsf.edu